Journal of Biomedical and Clinical Research 12(2): 162-165, doi: 10.2478/jbcr-2019-0024

A Case Report of Influence of Free Tyrosine Kinase/Placental Growth Factor (SFLT-1/PLGF) Ratio Test for Preeclampsia on Clinical Decision Making in Screening Positive Women

Polina Petkova Vasileva, Angel D. Yordanov, Valentina I. Mazneykova, Adelaida L. Ruseva, Dobromir D. Dimitrov

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits to copy and distribute the article for non-commercial purposes, provided that the article is not altered or modified and the original author and source are credited.

Citation: Vasileva P, Yordanov AD, Mazneykova VI, Ruseva AL, Dimitrov DD (2019) A Case Report of Influence of Free Tyrosine Kinase/Placental Growth Factor (SFLT-1/PLGF) Ratio Test for Preeclampsia on Clinical Decision Making in Screening Positive Women. Journal of Biomedical and Clinical Research 12(2): 162-165. https://doi.org/10.2478/jbcr-2019-0024

Abstract

Preeclampsia (PE) is characterized by hypertension and proteinuria after the 20th gestational week (GW). It is a significant cause of maternal and fetal perinatal morbidity and mortality during pregnancy. There is increasing evidence suggesting that PE is due to an impaired balance between maternal placental angiogenic and antiangiogenic factors that harm maternal vascular endothelium. The study aimed to assess the clinical and financial aspects of introducing into practice the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test to improve the management of preeclampsia and adverse pregnancy outcome, intrauterine growth retardation, iatrogenic prematurity, and placental abruption.We report a case study in which we used the sFlt-1/PlGF ratio in the management of a high-risk pregnancy. Unnecessary hospitalization was avoided, and the patient was managed appropriately.

Keywords

preeclampsia, sFlt-1/PlGF ratio, adverse pregnancy outcome